Gastric Neuroendocrine Neoplasias-Outcome Predictors-ENETS Staging and Grading System and Treatment Abstract #1151

Introduction: Detailed analysis to guide management decisions in gNEN is rare.
Aim(s): Characterize gNEN, identify prognostic factors, determine clinical outcome
Materials and methods: Retrospective analysis of gNEN treated from 1988 - 2014. Descriptive and survival analysis with SPSS 19.0
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.A. Stephan Felder

To read results and conclusion, please login ...

Further abstracts you may be interested in

#957 Outcome Predictors of Gastrinomas: The Role of ENETS Staging, Grading and Interdisciplinary Treatment
Introduction: Gastrinomas are rare neuroendocrine neoplasias (NEN) presenting with Zollinger‐Ellison‐syndrome (ZES).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Tischer E, Pascher A, ...
#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?
Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: PD Dr. Daniel Kaemmerer
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Josephine Schenk
#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni